Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Tight liquidity NBB
Cash and receivables cover 28 % of short-term debt in 2024; threshold 65 %.
-
Late annual account NBB
Fiscal year 2024 was filed 274 days after the legal deadline.
Financials
Financial year 2024
MaPharma from Charleroi, company number BE0799383730, closed financial year 2024 with a result of € -33,660 after tax. For that financial year MaPharma recorded a gross margin of € 45,535 and equity of € -104,883. Compared with financial year 2023, the result moved from € -73,223 to € -33,660. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 1, 2026.
€ -104,883
▼ € 33,660 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -33,660
▲ 54 % less loss than in 2023
Profit after tax over the fiscal year.
€ 10,448
▲ € 8,925 vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -106,883.
People and assets in 2024
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 53,950
▲ 1% vs 2023
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 7,217
▼ 35% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 79,348
▼ 34% vs 2023
€ 25,468 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 118,781
▼ 8% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 10,904
▲ 19% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|
| Gross margin | € 2,649 | € 45,535 | ▲ € 42,886 |
| Profit after taxes | € -73,223 | € -33,660 | ▲ € 39,562 |
| Equity | € -71,223 | € -104,883 | ▼ € 33,660 |
| Total debts | € 347,860 | € 361,613 | ▲ 4% |
| Cash | € 1,523 | € 10,448 | ▲ € 8,925 |
| Retained profit | € -73,223 | € -106,883 | ▼ € 33,660 |
| Bank debt | € 119,449 | € 79,348 | ▼ 34% |
| Balance sheet total | € 276,637 | € 256,730 | ▼ 7% |
Key figures of MaPharma, fiscal years 2023 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to MaPharma?
What happened at MaPharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 33,660. filed late Source: NBB ↗
- New establishment in Charleroi. KBO
- Dominique BODART became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 73,223 loss in 2023 to € 33,660 loss in 2024.
Paid € 259 in corporate taxes since 2023.
A new publication or filing at MaPharma? We notify you, reason included.
Follow MaPharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind MaPharma is Dominique BODART. Dominique BODART is also behind Cap Médical.
Directors
According to the 2024 annual accounts
since 2023
Establishments
Establishment units
Physical locations of this company
Rue Robesse 36 box B
6041 Charleroi
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
OVH Mail
Hosting
OVH, FR
DNS
OVH DNS
Website info
Features
Security
Details
- Company number
- 0799.383.730
- VAT number
- BE 0799.383.730
- Registered office
- Rue Robesse 36 bus B, 6041 Charleroi
- Names & denominations
- MaPharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 March 2023
- Peppol
- Active · Active since 30 Jan 2025
- Activities · NACE
Detailhandel in farmaceutische producten